Kindos Company Profile
What is the competitive landscape for KINDOS
KINDOS has six approved drugs.
Drugs and US Patents for Kindos
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kindos | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 218713-002 | Jul 30, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kindos | FLUOROURACIL | fluorouracil | INJECTABLE;INJECTION | 215699-001 | Feb 6, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kindos | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 218713-004 | Jul 30, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kindos | DALBAVANCIN HYDROCHLORIDE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 218929-001 | Nov 26, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

